Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

AIDS Vaccines and Pre-Exposure Prophylaxis: Is Synergy Possible?

19:29 EDT 18th April 2014 | BioPortfolio

Summary of "AIDS Vaccines and Pre-Exposure Prophylaxis: Is Synergy Possible?"

While the long-term goal is to develop highly effective AIDS vaccines, first generation vaccines may be only partially effective. Other HIV prevention modalities such as pre-exposure prophylaxis with antiretrovirals (PrEP) may have limited efficacy as well. The combined administration of vaccine and PrEP (VAXPREP), however, may have a synergistic effect leading to an overall benefit that is greater than the sum of the individual effects. We propose two test-of-concept trial designs for an AIDS vaccine plus oral or topical ARV. In one design, evidence that PrEP reduces the risk of HIV acquisition is assumed to justify offering it to all participants. A two-arm study comparing PrEP alone to VAXPREP is proposed in which 30 to 60 incident infections are observed to assess the additional benefit of vaccination on risk of infection and setpoint viral load. The demonstrated superiority of VAXPREP does not imply vaccine alone is efficacious. Similarly, the lack of superiority does not imply vaccine alone is ineffective, as antagonism could exist between vaccine and PrEP. In the other design, PrEP is assumed not to be in general use. A 2x2 factorial design is proposed in which high-risk individuals are randomized to one of 4 arms: placebo vaccine given with placebo PrEP, placebo vaccine given with PrEP, vaccine given with placebo PrEP, or VAXPREP. Between 60 and 210 infections are required to detect a benefit of vaccination with or without PrEP on risk of HIV acquisition or setpoint viral load, with fewer infections needed when synergy is present.

Affiliation

International AIDS Vaccine Initiative, Medical Affairs, 110 William Street, 27th Floor, New York, New York, United States, 10038-3901, +41 22 369 1391; jlexcler@iavi.org.

Journal Details

This article was published in the following journal.

Name: AIDS research and human retroviruses
ISSN: 1931-8405
Pages:

Links

PubMed Articles [5093 Associated PubMed Articles listed on BioPortfolio]

Recombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines.

HIV/AIDS is an important public health problem globally. An affordable, easy-to-deliver and protective HIV vaccine is therefore required to curb the pandemic from spreading further. Recombinant Salmon...

ESAT-6 (EsxA) and TB10.4 (EsxH) Based Vaccines for Pre- and Post-Exposure Tuberculosis Vaccination.

The ESX systems from Mycobacterium tuberculosis are responsible for the secretion of highly immunogenic proteins of key importance for bacterial survival and growth. The two prototypic proteins, ESAT-...

Sexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis delivery.

Despite evidence supporting pre-exposure prophylaxis (PrEP) efficacy, there are concerns regarding the feasibility of widespread PrEP implementation among men who have sex with men (MSM). To inform th...

Evolution of electroporated DNA vaccines.

Vaccines have evolved for hundreds of years, but all utilize the premise that safely pre-exposing the host to some component of a pathogen allows for enhanced immune recognition, and potential protect...

Tensions Between the Epidemiology and Psychology of HIV Risk: Implications for Pre-exposure Prophylaxis.

This study focuses on psychological differences in risk-taking patterns and their association with risk compensation motivations in the context of pre-exposure prophylaxis (PrEP). Participants were 25...

Clinical Trials [2314 Associated Clinical Trials listed on BioPortfolio]

Effect of Repeated Exposures to Compressed Air on Patients With AIDS

The exposure of human beings to markedly altered environments (ambient pressure and inhaled gas mixtures) has profound effects on their innate immune capacity to effectively combat viral i...

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

The purpose of this study is to evaluate the long-term consequences of HIV-1 infections that occurred in association with known, but discouraged, high-risk behaviors in persons who have re...

The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys

The purpose of this study is to see if an investigational vaccine can make antibodies (proteins found in blood) in humans that will influence the course of an AIDS-like disease in monkeys....

Purified Rabies Vaccine for Human Use (Chick-Embryo Cell)

Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.

Safety and Performance Evaluation of CircuLite Synergy

The purpose of the study is to demonstrate the safety and functionality of the CircuLite Synergy Pocket Circulatory Assist Device.

Medical and Biotech [MESH] Definitions

Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.

Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.

The prevention of infection or disease following exposure to a pathogen. This is most frequently addressed by administering a vaccine or anti-viral medication following exposure to a virus.

Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.

Vaccines or candidate vaccines used to prevent infection with viruses from the genus SIMPLEXVIRUS. This includes vaccines for HSV-1 and HSV-2.

Search BioPortfolio: